Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sucampo Pharma Americas, LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has completed 12 weeks of blinded treatment in NCT00595946 or NCT00597428
Will continue to be treated consistently for chronic, non-cancer-related pain with any full agonist opiate and will continue opiate therapy for the duration of the study
Willing to continue to abstain from use of disallowed medications as defined per protocol
You may not be if
Has newly diagnosed impaired renal function identified at the Screening Visit \[i.e., serum creatinine concentration \> 1.8 milligrams per deciliter (mg/dL)\]
Has experienced an unexplained and/or clinically significant weight loss defined as \> 5% within 90 days prior to Screening Visit.
Has plans to participate in another trial with an investigational drug or device during the course of the extension study
Clareo Health | Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
